Latest market price
7.26
-0.42-5.47%
OverviewShort InterestFilings
IMMXQT68Immix Biopharma, Inc.·NASDAQ
7.26-5.47%
TA
Loading chart...
Signal & projected range
QT Score downgradeHistorical pattern — not a prediction
Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QURE-7.49%$22.97RARE+1.24%$16.30NUVB-3.57%$4.59TRAX-0.07%$45.05NTLA-6.50%$11.66ABSI-12.94%$9.69URGN+5.01%$34.36MAZE-3.53%$30.37
Snapshot
Index—P/E—EPS (ttm)-0.88Insider Own11.34%Shs Outstand82.90MPerf Week-9.93%
Market Cap601.88MForward P/E—EPS next Y-0.95Insider Trans0.00%Shs Float58.27MPerf Month-25.00%
Enterprise Value370.88MPEG—EPS next Q-0.18Short Float18.38%Perf Quarter-22.19%
Income-41.00MP/S—EPS this Y—Short Ratio6.49Perf Half Y-23.42%
Sales0.00P/B2.63EPS next Y—ROA-16.69%Short Interest10.71MPerf YTD38.81%
Book/sh2.76P/C2.59EPS next 5Y—ROE-38.44%52W High15.10 -51.92%Perf Year97.82%
Cash/sh2.80P/FCF—EPS past 3/5Y—ROIC-18.19%52W Low2.85 154.74%Perf 3Y96.75%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility6.12% 6.14%Perf 5Y—
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)0.61Perf 10Y—
Dividend Ex-Date—Quick Ratio25.13Sales Y/Y TTM—Profit Margin0.00%RSI (14)27.23Recom2.00
Dividend Gr. 3/5Y—Current Ratio25.13EPS Q/Q18.18%SMA20-14.73%Beta1.63Target Price22.67
Payout0.00%Debt/Eq0.00Sales Q/Q—SMA50-33.35%Rel Volume0.99Prev Close7.68
Employees21LT Debt/Eq0.00EarningsNov 06SMA200-23.54%Avg Volume1.52MPrice7.26
IPO DateDec 16, 2021Option/ShortYes / YesEPS/Sales Surpr.-5.00% —Net Debt/EBITDA—Volume1,507,046Change-5.47%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-29-26ReiteratedMizuho SecuritiesOutperform$26 → $23
Oct-20-26ReiteratedMorgan StanleyOverweight$19 → $20
Sep-15-26ReiteratedMizuhoOutperform$14 → $26
Aug-11-26ReiteratedMorgan StanleyOverweight$19
Aug-10-26ReiteratedHC Wainwright & Co.Buy$20 → $25
May-22-26ReiteratedHC Wainwright & Co.Buy$15 → $20
Mar-27-26ReiteratedHC Wainwright & Co.Buy$12 → $15
Feb-09-26InitiatedMizuhoOutperform$14
Dec-09-25ReiteratedHC Wainwright & Co.Buy$7.00 → $12
Jul-01-24InitiatedH.CBuy$7.00
Latest News· Times ET
Oct-27-26
Oct-27-2611:56AM
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?Yahoo
Oct-21-26
Oct-21-2612:29AM
Immix Biopharma (IMMX) Stock Sees Modest Fair Value Lift After Split Analyst RevisionsYahoo
Oct-05-26
Oct-05-2608:45AM
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conferenceglobenewswire.com
08:02AM
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Studydefenseworld.net
Sep-30-26
Sep-30-2605:15PM
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stockglobenewswire.com
06:41AM
Immix Biopharma (NASDAQ:IMMX) Stock Jumps 4.1% – Should You Buy?defenseworld.net
Sep-29-26
Sep-29-2611:42AM
Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call TranscriptSeekingAlpha
07:05AM
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stockglobenewswire.com
07:00AM
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosisglobenewswire.com
Sep-15-26
Sep-15-2605:41AM
Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26Benzinga
Aug-25-26
Aug-25-2603:47AM
Immix Biopharma (NASDAQ:IMMX) Reaches New 12-Month High – Still a Buy?defenseworld.net
Aug-13-26
Aug-13-2610:00AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMXprnewswire.com
Aug-11-26
Aug-11-2606:23PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMXglobenewswire.com
07:56AM
Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19Benzinga
Aug-10-26
Aug-10-2604:10AM
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25Benzinga
Company

Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
0000————
Cost of Goods Sold Incl. D&A
0000————
Gross Profit
0000————
Selling, General and Administrative Excl. Other2014117————
Research and Development2216119————
Other Operating Expense0010————
Operating Income-42-30-23-16————
Interest Expense
0000————
Unusual Expense
————————
Non-Operating Income (Expense)2111————
Net Income Before Taxes-41-29-22-16————
Income Taxes
0000————
Consolidated Net Income-41-29-22-15————
Net Income From Continuing Operations-41-29-22-16————
Net Income-41-29-22-15————
EPS (Recurring)-0.88-0.89-0.76-0.89————
EPS (Basic, Before Extraordinaries)-0.88-0.89-0.76-0.89————
EPS (Diluted)-0.88-0.89-0.76-0.89————
EBITDA-40-30-22-16————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio
————————
Gross Margin
————————
Operating Margin
————————
Net Margin
————————
Shares Outstanding64332817————
Market Capitalization46517362118————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$16.35$12.28$8.21$4.15$0.08● Close Price0.00K2.51K5.02K7.53K10.04KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Rachman Ilya MCEO and ChairmanDec 10 '25Buy6.677464,9761,141,683Dec 10
Morris Gabriel SCFODec 10 '25Buy6.587705,067291,429Dec 10
Morris Gabriel SCFODec 08 '25Option Exercise0.80216,000172,800426,844Dec 10
Rachman Ilya MCEO and ChairmanSep 17 '25Buy2.022,5005,0501,140,937Sep 17
Morris Gabriel SCFOSep 16 '25Buy1.972,6005,122290,659Sep 17
Rachman Ilya MCEO and ChairmanJun 18 '25Buy2.292,1784,9991,138,437Jun 20
Morris Gabriel SCFOJun 18 '25Buy2.282,2255,071288,059Jun 20
Hsu JasonDirectorDec 23 '24Buy2.1940,00087,680893,000Dec 26
Hsu JasonDirectorDec 20 '24Buy2.177,70016,678853,000Dec 26
Hsu JasonDirectorAug 22 '24Buy2.258,10018,233845,300Aug 26
Hsu JasonDirectorAug 21 '24Buy2.2315,00033,390837,200Aug 26
Ng CareyDirectorAug 16 '24Buy1.8610,00018,60020,000Aug 19
Hsu JasonDirectorJul 24 '24Buy2.156,00012,877822,200Jul 31
Hsu JasonDirectorJul 18 '24Buy2.073,2006,639816,200Jul 31
Rachman Ilya MCEO and ChairmanJun 07 '24Buy2.132,6005,5381,136,259Jun 10
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.